Literature DB >> 17967862

Recombinant holotoxoid vaccine against botulism.

Christina L Pier1, William H Tepp, Marite Bradshaw, Eric A Johnson, Joseph T Barbieri, Michael R Baldwin.   

Abstract

The botulinum neurotoxins (BoNT) are the most toxic proteins for humans and designated "Category A Select Agents." The current vaccine against botulism is in limited supply, and there is a need to develop new vaccine strategies. A recombinant BoNT/A toxoid was produced in Clostridium botulinum that contained a double amino acid substitution, R363A Y365F (termed BoNT/A(RYM)). BoNT/A(RYM) was noncatalytic for SNAP25 and nontoxic for mice. Immunization with BoNT/A(RYM) protected mice from challenge at levels that were similar to chemically inactivated BoNT/A toxoid. BoNT/A(RYM) elicited an immune response against the light-chain and heavy-chain components of the toxin. Neutralizing anti-BoNT/A(RYM) sera blocked BoNT toxicity in primary cortical neurons and blocked ganglioside binding by the heavy chain. BoNT/A(RYM) represents a viable vaccine candidate for a holotoxoid against botulism.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17967862      PMCID： PMC2223665          DOI： 10.1128/IAI.00843-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  31 in total

1.  Purification of Clostridium botulinum type A neurotoxin.

Authors:  C J Malizio; M C Goodnough; E A Johnson
Journal:  Methods Mol Biol       Date:  2000

2.  Botulinum neurotoxin B-host receptor recognition: it takes two receptors to tango.

Authors:  Michael R Baldwin; Jung-Ja P Kim; Joseph T Barbieri
Journal:  Nat Struct Mol Biol       Date:  2007-01       Impact factor: 15.369

Review 3.  Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.

Authors:  E A Johnson
Journal:  Annu Rev Microbiol       Date:  1999       Impact factor: 15.500

4.  Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris.

Authors:  M P Byrne; R W Titball; J Holley; L A Smith
Journal:  Protein Expr Purif       Date:  2000-04       Impact factor: 1.650

Review 5.  Botulinum toxin as a biological weapon: medical and public health management.

Authors:  S S Arnon; R Schechter; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; J Hauer; M Layton; S Lillibridge; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; D L Swerdlow; K Tonat
Journal:  JAMA       Date:  2001-02-28       Impact factor: 56.272

6.  Modeling Pichia pastoris growth on methanol and optimizing the production of a recombinant protein, the heavy-chain fragment C of botulinum neurotoxin, serotype A.

Authors:  W Zhang; M A Bevins; B A Plantz; L A Smith; M M Meagher
Journal:  Biotechnol Bioeng       Date:  2000-10-05       Impact factor: 4.530

Review 7.  Development of vaccines for prevention of botulism.

Authors:  M P Byrne; L A Smith
Journal:  Biochimie       Date:  2000 Sep-Oct       Impact factor: 4.079

8.  Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes.

Authors:  Michael R Baldwin; Joseph T Barbieri
Journal:  Biochemistry       Date:  2007-02-21       Impact factor: 3.162

Review 9.  Basic immunological aspects of botulinum toxin therapy.

Authors:  M Zouhair Atassi
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

10.  Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes.

Authors:  Mohammed Sebaihia; Michael W Peck; Nigel P Minton; Nicholas R Thomson; Matthew T G Holden; Wilfrid J Mitchell; Andrew T Carter; Stephen D Bentley; David R Mason; Lisa Crossman; Catherine J Paul; Alasdair Ivens; Marjon H J Wells-Bennik; Ian J Davis; Ana M Cerdeño-Tárraga; Carol Churcher; Michael A Quail; Tracey Chillingworth; Theresa Feltwell; Audrey Fraser; Ian Goodhead; Zahra Hance; Kay Jagels; Natasha Larke; Mark Maddison; Sharon Moule; Karen Mungall; Halina Norbertczak; Ester Rabbinowitsch; Mandy Sanders; Mark Simmonds; Brian White; Sally Whithead; Julian Parkhill
Journal:  Genome Res       Date:  2007-05-22       Impact factor: 9.043
View more
  29 in total

1.  Regulation of neurotoxin production and sporulation by a Putative agrBD signaling system in proteolytic Clostridium botulinum.

Authors:  Clare M Cooksley; Ian J Davis; Klaus Winzer; Weng C Chan; Michael W Peck; Nigel P Minton
Journal:  Appl Environ Microbiol       Date:  2010-05-07       Impact factor: 4.792

2.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

Review 3.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

4.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

5.  In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A.

Authors:  Easwaran Ravichandran; Pavithra Janardhanan; Kruti Patel; Stephen Riding; Shuowei Cai; Bal Ram Singh
Journal:  Pharm Res       Date:  2015-11-03       Impact factor: 4.200

6.  Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A.

Authors:  Sabine Pellett; William H Tepp; Larry H Stanker; Philip A Band; Eric A Johnson; Konstantin Ichtchenko
Journal:  Biochem Biophys Res Commun       Date:  2011-02-01       Impact factor: 3.575

7.  Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.

Authors:  Clifford Shone; Heidi Agostini; Joanna Clancy; Mili Gu; Huei-Hsiung Yang; Yanfang Chu; Virginia Johnson; Makie Taal; Joanna McGlashan; John Brehm; Xiaomi Tong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

8.  DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge.

Authors:  Veronica L Scott; Daniel O Villarreal; Natalie A Hutnick; Jewell N Walters; Edwin Ragwan; Khalil Bdeir; Jian Yan; Niranjan Y Sardesai; Adam C Finnefrock; Danilo R Casimiro; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Enhancing toxin-based vaccines against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Madison Zuverink; Eric A Johnson; Sabine Pellet; Joseph T Barbieri
Journal:  Vaccine       Date:  2018-01-04       Impact factor: 3.641

10.  Characterization of new formalin-detoxified botulinum neurotoxin toxoids.

Authors:  James E Keller
Journal:  Clin Vaccine Immunol       Date:  2008-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.